is mounjaro a semaglutide compound Ozempic® (semaglutide) and Mounjaro™ (tirzepatide), major breakthrough for the treatment of obesity TrimRX | Mounjaro to Ozempic:

The platform cannot guarantee that any individual will receive a prescription-that clinical determination rests with the evaluating provider

Light daily doses deliver real results fast

Based on typical FDA review timelines and the current progress of trials, analysts project: Phase 3 trial completion: Late 2025 to early 2026 FDA submission: First half of 2026 Potential FDA approval: Q3 2026 to Q1 2027 Commercial availability: 2-3 months post-approval The FDA has not granted any special designations (Breakthrough Therapy, Fast Track) for Retatrutides obesity indication, which may mean standard review timelines apply

Authentication, however, should never trade convenience for safety

Retatrutide belongs to a new class of drugs called triple agonists

Administer within one hour prior to the first meal of the day